Targeted alpha-particle therapy – possibilities of post-therapeutic imaging

Monika Tulik; Jolanta Kunikowska

doi:10.2478/pjmpe-2024-0030

.blurhash-client-img { display: none !important; }

Targeted alpha-particle therapy – possibilities of post-therapeutic imaging

Polish Journal of Medical Physics and Engineering

Volume 30 (2024): Issue 4 (December 2024)

By: Monika Tulik and Jolanta Kunikowska

Open Access

|Dec 2024

Abstract

The article presents the physical foundations of targeted radioisotope therapy with alpha particles, difficulties of imaging after an administration of alpha emitters, as well as current research trends and possibilities of their post-therapeutic imaging.

References

Morgan KA, Rudd SE, Noor A, Donnelly PS. Theranostic Nuclear Medicine with Gallium-68, Lutetium-177, Copper-64/67, Actinium-225, and Lead-212/203 Radionuclides. Chem Rev. 2023;123(20):12004-12035. https://doi.org/10.1021/acs.chemrev.3c00456
Search in Google Scholar Back to article
Leidermark E, Hallqvist A, Jacobsson L, et al. Estimating the Risk for Secondary Cancer After Targeted α-Therapy with211At Intraperitoneal Radioimmunotherapy. J Nucl Med. 2022;64(1):165-172. https://doi.org/10.2967/jnumed.121.263349
Search in Google Scholar Back to article
Reinecke MJ, Ahlers G, Burchert A, et al. Second primary malignancies induced by radioactive iodine treatment of differentiated thyroid carcinoma — a critical review and evaluation of the existing evidence. Eur J Nucl Med Mol Imaging. 2022;49(9):3247-3256. https://doi.org/10.1007/s00259-022-05762-4
Search in Google Scholar Back to article
Kunikowska J, Królicki L, Hubalewska-Dydejczyk A, Mikołajczak R, Sowa-Staszczak A, Pawlak D. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option? Eur J Nucl Med Mol Imaging. 2011;38(10):1788-1797. https://doi.org/10.1007/s00259-011-1833-x
Search in Google Scholar Back to article
Baum RP, Kulkarni HR, Singh A, et al. Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms. Oncotarget. 2018;9(24):16932-16950. https://doi.org/10.18632/oncotarget.24524
Search in Google Scholar Back to article
Hänscheid H, Lassmann M, Verburg FA. Determinants of target absorbed dose in radionuclide therapy. Zeitschrift für Medizinische Physik. 2023;33(1):82-90. https://doi.org/10.1016/j.zemedi.2022.10.001
Search in Google Scholar Back to article
Pouget JP, Constanzo J. Revisiting the Radiobiology of Targeted Alpha Therapy. Front Med. 2021;8. https://doi.org/10.3389/fmed.2021.692436
Search in Google Scholar Back to article
Poty S, Francesconi LC, McDevitt MR, Morris MJ, Lewis JS. α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies—Part 1. J Nucl Med. 2018;59(6):878-884. https://doi.org/10.2967/jnumed.116.186338
Search in Google Scholar Back to article
Sgouros G, Roeske JC, McDevitt MR, et al. MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy. J Nucl Med. 2010;51(2):311-328. https://doi.org/10.2967/jnumed.108.058651
Search in Google Scholar Back to article
Koh T, Bezak E, Chan D, Cehic G. Targeted alpha-particle therapy in neuroendocrine neoplasms: A systematic review. World J Nucl Med. 2021;20(04):329-335. https://doi.org/10.4103/wjnm.wjnm_160_20
Search in Google Scholar Back to article
Shi M, Jakobsson V, Greifenstein L, et al. Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists. Front Med. 2022;9. https://doi.org/10.3389/fmed.2022.1034315
Search in Google Scholar Back to article
Parker C, Nilsson S, Heinrich D, et al. Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer. N Engl J Med. 2013;369(3):213-223. https://doi.org/10.1056/nejmoa1213755
Search in Google Scholar Back to article
Zhang J, Qin S, Yang M, Zhang X, Zhang S, Yu F. Alpha-emitters and targeted alpha therapy in cancer treatment. iRADIOLOGY. 2023;1(3):245-261. https://doi.org/10.1002/ird3.30
Search in Google Scholar Back to article
Jabbar T, Bashir S, Babar MI. Review of current status of targeted alpha therapy in cancer treatment. Nucl Med Rev. 2023;26(0):54-67. https://doi.org/10.5603/nmr.2023.0003
Search in Google Scholar Back to article
Kunikowska J, Morgenstern A, Pełka K, Bruchertseifer F, Królicki L. Targeted alpha therapy for glioblastoma. Front Med. 2022;9. https://doi.org/10.3389/fmed.2022.1085245
Search in Google Scholar Back to article
Seo Y. Quantitative Imaging of Alpha-Emitting Therapeutic Radiopharmaceuticals. Nucl Med Mol Imaging. 2019;53(3):182-188. https://doi.org/10.1007/s13139-019-00589-8
Search in Google Scholar Back to article
Lassmann M, Eberlein U. Targeted alpha-particle therapy: imaging, dosimetry, and radiation protection. Ann ICRP. 2018;47(3-4):187-195. https://doi.org/10.1177/0146645318756253
Search in Google Scholar Back to article
Hindorf C, Chittenden S, Aksnes AK, Parker C, Flux GD. Quantitative imaging of 223Ra-chloride (Alpharadin) for targeted alpha-emitting radionuclide therapy of bone metastases. Nuclear Medicine Communications. 2012;33(7):726-732. https://doi.org/10.1097/mnm.0b013e328353bb6e
Search in Google Scholar Back to article
Carrasquillo JA, O’Donoghue JA, Pandit-Taskar N, et al. Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2013;40(9):1384-1393. https://doi.org/10.1007/s00259-013-2427-6
Search in Google Scholar Back to article
Chittenden SJ, Hindorf C, Parker CC, et al. A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of 223Ra-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal Metastases. J Nucl Med. 2015;56(9):1304-1309. https://doi.org/10.2967/jnumed.115.157123
Search in Google Scholar Back to article
Yoshida K, Kaneta T, Takano S, et al. Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases. Ann Nucl Med. 2016;30(7):453-460. https://doi.org/10.1007/s12149-016-1093-8
Search in Google Scholar Back to article
Pacilio M, Ventroni G, De Vincentis G, et al. Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting 223Ra-dichloride. Eur J Nucl Med Mol Imaging. 2015;43(1):21-33. https://doi.org/10.1007/s00259-015-3150-2
Search in Google Scholar Back to article
Murray I, Rojas B, Gear J, Callister R, Cleton A, Flux GD. Quantitative Dual-Isotope Planar Imaging of Thorium-227 and Radium-223 Using Defined Energy Windows. Cancer Biotherapy and Radiopharmaceuticals. 2020;35(7):530-539. https://doi.org/10.1089/cbr.2019.3554
Search in Google Scholar Back to article
Sgouros G, Ballangrud AM, Jurcic JG, et al. Pharmacokinetics and Dosimetry of an α-Particle Emitter Labeled Antibody: 213Bi-HuM195 (Anti-CD33) in Patients with Leukemia. J Nucl Med. 1999;40:1935-1949.
Search in Google Scholar Back to article
Cordier D, Forrer F, Bruchertseifer F, et al. Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial. Eur J Nucl Med Mol Imaging. 2010;37(7):1335-1344. https://doi.org/10.1007/s00259-010-1385-5
Search in Google Scholar Back to article
Kratochwil C, Bruchertseifer F, Giesel FL, et al. 225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2016;57(12):1941-1944. https://doi.org/10.2967/jnumed.116.178673
Search in Google Scholar Back to article
Kamaleshwaran K, Suneelkumar M, Madhusairam R, Radhakrishnan E, Arunpandiyan S, Arnold V. Whole-body and single-photon emission computed tomography/computed tomography postpeptide receptor alpha radionuclide therapy images of actinium 225-tetraazacyclododecanetetraacetic Acid–Octreotide as a primary modality of treatment in a patient with advanced rectal neuroendocrine tumor with metastases. Indian J Nucl Med. 2020;35(3):226. https://doi.org/10.4103/ijnm.ijnm_58_20
Search in Google Scholar Back to article
Ocak M, Toklu T, Demirci E, Selçuk N, Kabasakal L. Post-therapy imaging of 225Ac-DOTATATE treatment in a patient with recurrent neuroendocrine tumor. Eur J Nucl Med Mol Imaging. 2020;47(11):2711-2712. https://doi.org/10.1007/s00259-020-04725-x
Search in Google Scholar Back to article
Gosewisch A, Schleske M, Gildehaus FJ, et al. Image-based dosimetry for 225Ac-PSMA-I&T therapy using quantitative SPECT. Eur J Nucl Med Mol Imaging. 2020;48(4):1260-1261. https://doi.org/10.1007/s00259-020-05024-1
Search in Google Scholar Back to article
Delker A, Schleske M, Liubchenko G, et al. Biodistribution and dosimetry for combined [177Lu]Lu-PSMA-I&T/[225Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging. Eur J Nucl Med Mol Imaging. 2023;50(5):1280-1290. https://doi.org/10.1007/s00259-022-06092-1
Search in Google Scholar Back to article
Benabdallah N, Scheve W, Dunn N, et al. Practical considerations for quantitative clinical SPECT/CT imaging of alpha particle emitting radioisotopes. Theranostics. 2021;11(20):9721-9737. https://doi.org/10.7150/thno.63860
Search in Google Scholar Back to article
Liubchenko G, Böning G, Zacherl M, et al. Image-based dosimetry for [225Ac]Ac-PSMA-I&T therapy and the effect of daughter-specific pharmacokinetics. Eur J Nucl Med Mol Imaging. 2024;51(8):2504-2514. https://doi.org/10.1007/s00259-024-06681-2
Search in Google Scholar Back to article
Tulik M, Kuliński R, Tabor Z, et al. Quantitative SPECT/CT imaging of actinium-225 for targeted alpha therapy of glioblastomas. EJNMMI Phys. 2024;11(1). https://doi.org/10.1186/s40658-024-00635-1
Search in Google Scholar Back to article
Takahashi A, Kajiya R, Baba S, Sasaki M. Monte Carlo simulation study to explore optimum conditions for Astatine-211 SPECT. Radiol Phys Technol. 2023;16(1):102-108. https://doi.org/10.1007/s12194-023-00702-9
Search in Google Scholar Back to article
Turkington TG, Zalutsky MR, Jaszczak RJ, Garg PK, Vaidyanathan G, Coleman RE. Phys Med Biol. 1993;38(8):1121-1130. https://doi.org/10.1088/0031-9155/38/8/010
Search in Google Scholar Back to article
Müller C, Vermeulen C, Köster U, et al. Alpha-PET with terbium-149: evidence and perspectives for radiotheragnostics. EJNMMI radiopharm chem. 2016;1(1). https://doi.org/10.1186/s41181-016-0008-2
Search in Google Scholar Back to article
Mikalsen LTG, Kvassheim M, Stokke C. Optimized SPECT Imaging of224Ra α-Particle Therapy by212Pb Photon Emissions. J Nucl Med. 2023;64(7):1131-1137. https://doi.org/10.2967/jnumed.122.264455
Search in Google Scholar Back to article
Kvassheim M, Tornes AJK, Juzeniene A, Stokke C, Revheim MER. Imaging of 212Pb in mice with a clinical SPECT/CT. EJNMMI Phys. 2023;10(1). https://doi.org/10.1186/s40658-023-00571-6
Search in Google Scholar Back to article
Kvassheim M, Revheim MER, Stokke C. Quantitative SPECT/CT imaging of lead-212: a phantom study. EJNMMI Phys. 2022;9(1). https://doi.org/10.1186/s40658-022-00481-z
Search in Google Scholar Back to article
Meredith RF, Torgue J, Azure MT, et al. Pharmacokinetics and Imaging of212Pb-TCMC-Trastuzumab After Intraperitoneal Administration in Ovarian Cancer Patients. Cancer Biotherapy and Radiopharmaceuticals. 2014;29(1):12-17. https://doi.org/10.1089/cbr.2013.1531
Search in Google Scholar Back to article

Articles in this issue

DOI: https://doi.org/10.2478/pjmpe-2024-0030 | Journal eISSN: 1898-0309 | Journal ISSN: 1425-4689

Journal RSS Feed

Language: English

Submitted on: Jul 31, 2024

Accepted on: Nov 6, 2024

Published on: Dec 23, 2024

Published by: Polish Society of Medical Physics

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

targeted alpha-particle therapy,

alpha particles,

imaging

Related subjects:

Medicine,

Biomedical engineering,

Physics,

Technical and applied physics,

Medical physics

© 2024 Monika Tulik, Jolanta Kunikowska, published by Polish Society of Medical Physics
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Volume 30 (2024): Issue 4 (December 2024)